Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
This raises the risk of transmitting the virus while interrupting treatment as part of a study.
Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston
The researchers studied a new compound that blocked a key viral protein that prompts infected cells to produce more virus.
Six percent of a group of pregnant Canadian women saw their virus rise to detectable levels close to delivery.
For those who achieve viral suppression within nine months of starting meds, the rebound risk declines steadily over seven years.
People coinfected with HIV and hepatitis C are more likely to develop liver fibrosis if they experience an HIV viral load rebound, rather than...
Echoing the disappointment of “Mississippi baby” case, a second child’s virus has rebounded after he was suspected to be functionally cur...
The child has experienced a resurgence of the virus and is once again taking antiretroviral therapy.
Two HIV-positive men who each displayed no signs of the virus after stem cell transplants to treat their lymphoma have both experienced a vira...
Having a higher viral load when beginning HIV treatment and taking longer to fully suppress the virus each up the risk of a viral rebound.
The topical antifungal agent Ciclopirox clears HIV by promoting infected cells to effectively commit suicide and also prevents viral rebound a...
Fourteen French adults treated within two months of infection maintain undetectable virus levels after stopping antiretroviral (ARV) therapy.
People on antiretroviral (ARV) therapy with fully suppressed virus were more likely to see virus levels go up if they also reported physical s...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.